Sarepta Prepared For DMD Gene Therapy Launch Despite Regulatory Setbacks
As Q1 Earnings Beat Expectations
Despite obstacles on the regulatory path for the firm’s Duchenne muscular dystrophy gene therapy, analysts and Sarepta itself seem confident about accelerated approval prospects, with plans already in place for launch.
